Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data
Immunovant (IMVT) reported its second quarter fiscal 2026 results, highlighted by positive clinical data for IMVT-1402 in rheumatoid arthritis. The 600 mg dose demonstrated a 92.5% ACR20 response rate compared to 75.6% for placebo at week 28, showing significant efficacy in difficult-to-treat patients. However, the company announced it is unlikely to advance IMVT-1402 for Sjögren’s Disease due to a changing competitive landscape. Financially, Immunovant reported a net loss of $97.2 million ($0.47 per share), an improvement from the previous year's loss of $126.5 million. The company maintains a strong cash position of $722.3 million as of September 30, 2026, which management expects will fund operations through the potential commercial launch for Graves’ disease. Topline data for registrational trials in Graves’ Disease and Myasthenia Gravis are expected in 2027.
Topics: biotechnology clinical trial results drug efficacy rheumatoid arthritis
Read the full article at Motley Fool
Part of the story Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data (3 articles)